Irbesartan E Idroclorotiazide Alter

Irbesartan and Hydrochlorothiazide, the active ingredients in Irbesartan E Idroclorotiazide Alter, are an angiotensin II receptor blocker and a thiazide diuretic presented as a tablet for oral use. They treat hypertension in adult patients, often when combination therapy is required to achieve blood‑pressure control.

GNH USA supplies Irbesartan E Idroclorotiazide Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is indicated for the management of hypertension, a condition characterized by elevated arterial pressure.

- Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Secondary hypertension: provides effective blood‑pressure control when underlying causes are present. - Hypertension with fluid retention: combines vasodilation and diuresis to improve overall blood‑pressure management.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first dose. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild reductions in potassium or sodium levels. - Headache: occasional mild to moderate intensity. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: dangerously high potassium levels. - Allergic reactions: rash, itching, or swelling. - Blood dyscrasias: rare cases of leukopenia or thrombocytopenia.

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Renal function assessment: check serum creatinine and eGFR regularly. - Electrolyte surveillance: monitor potassium and sodium levels, especially in patients on other diuretics. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy and lactation: avoid use unless clearly needed; safety not established. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Irbesartan/HCTZ may interact with several medicines; review patient medication lists carefully.

Major Interactions (Avoid): - ACE inhibitors or aliskiren: combined use can cause severe hyperkalemia and renal impairment. - Potassium‑sparing diuretics: increase risk of dangerous hyperkalemia. - Lithium: may raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: can blunt antihypertensive effect and affect renal function. - Other antihypertensives: additive blood‑pressure lowering may require dose adjustments. - CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan plasma concentrations.